Compare CSL & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSL | FMS |
|---|---|---|
| Founded | 1917 | 1996 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Misc Health and Biotechnology Services |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1B | 14.2B |
| IPO Year | 1994 | N/A |
| Metric | CSL | FMS |
|---|---|---|
| Price | $352.67 | $23.46 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 6 | 2 |
| Target Price | ★ $390.00 | $30.00 |
| AVG Volume (30 Days) | 364.7K | ★ 615.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | 1.24% | ★ 2.48% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 17.12 | N/A |
| Revenue | ★ $5,003,600,000.00 | N/A |
| Revenue This Year | $2.21 | $1.41 |
| Revenue Next Year | $4.25 | $4.11 |
| P/E Ratio | $20.75 | ★ $15.62 |
| Revenue Growth | ★ 9.08 | N/A |
| 52 Week Low | $293.43 | $20.96 |
| 52 Week High | $435.92 | $30.46 |
| Indicator | CSL | FMS |
|---|---|---|
| Relative Strength Index (RSI) | 31.82 | 50.58 |
| Support Level | $344.01 | $23.38 |
| Resistance Level | $398.08 | $24.08 |
| Average True Range (ATR) | 13.16 | 0.43 |
| MACD | -7.69 | -0.09 |
| Stochastic Oscillator | 18.69 | 46.78 |
Carlisle Companies Inc is a holding company. The company manufactures and sells single-ply roofing products and warranted systems and accessories for the commercial building industry. The company is organized into two segments including Carlisle Construction Materials and Carlisle Weatherproofing Technologies. The company's product portfolio includes moisture protection products, protective roofing underlayments, integrated air and vapor barriers, spray polyurethane foam and coating systems, and others. The majority of the company's revenue comes from the Carlisle Construction Materials segment, and more than half of the total revenue is earned in the United States.
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.